Drug Channels Acquired by HMP Global
Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.
Adam J. Fein, Ph.D.
HMP Global, a healthcare education company, will acquire Drug Channels Institute. Founded in 2006 by Adam J. Fein, Ph.D., Drug Channels is a market intelligence company focused on the pharmaceutical industry. It provides webinars and industry reports on pharmaceutical economic issues and drug supply and distribution. Terms of the agreement were not disclosed.
As part of the integration, Drug Channels leadership will remain in place, with Fein becoming president, Drug Channels Institute, and Paula Fein assuming the role of vice president, business development.
Adam Fein is a well-known thought leader in the pharmaceutical industry providing insight and analysis on drug pricing, pharmacy benefit managers, the specialty drug market, drug reimbursement, and healthcare reform. He is known for his humor in making the industry more accessible for readers.
On a blog post on the Drug Channels website, Adam Fein said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.
HMP produces in person and virtual medical education events and provides news and clinical information for healthcare providers. It produces about 50 journals/websites and 400 events and serves oncology, neurology, psychiatry and behavioral health, gastroenterology, cardiovascular, dermatology and rheumatology.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Lifts Safety Restrictions on CAR T Therapies After Reviewing Real-World Data
July 2nd 2025FDA officials have determined that information regarding the risks for six CAR T-cell therapies can be communicated through product labeling, which includes a boxed warning for the risks of cytokine release syndrome and neurological toxicities.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
